Bradley Boeve, a Mayo Clinic neurologist and the grant’s co-principal investigator. “Information that predicts the timing and type of synucleinopathy disorder is almost certainly hidden in one or more of the biomarkers that will be assessed as part of this study," said Dr. But first scientists need to identify a set of findings on specialized tests, or biomarkers, of impending neurological disease in people with REM sleep behavior disorder. Several drugs and immunotherapies targeting alpha-synuclein are being developed, and they may become available for clinical trials in REM sleep behavior disorder. As that area becomes damaged, people start thrashing around as they dream. Such clumps often coalesce early in the course of the diseases in a part of the brain that paralyzes the body during REM sleep. REM sleep behavior disorder is connected to diseases caused by an accumulation of abnormal clumps of the protein alpha-synuclein in the brain. Acting out dreams is an early sign that something in the brain is not functioning quite as it should. Normally, people are paralyzed during REM sleep, the phase of sleep in which dreaming occurs. And we certainly don't know how to prevent it.” “We have no way of predicting whether and how soon someone will develop one of these diseases or which one they will get. Yo-El Ju, a Washington University neurologist and co-principal investigator. “The odds of people with REM sleep behavior disorder developing a neurodegenerative disease are pretty alarming, and currently there are no treatments to decrease that risk,” said Dr. Biomarkers are important to help precisely define what stage of disease people are in, so that better targeted therapies can be provided.” So far, we have very good clinical predictors of disease, but biomarker research has still been catching up. “When we do this, we can start planning trials to prevent disease. Ronald Postuma of The Neuro and the Research Institute of the McGill University Health Centre. “The most important goal of this research is to find ways to reliably identify early Parkinson’s disease, Lewy body dementia and multiple system atrophy,” said co-principal investigator Dr. REM sleep behavior disorder is linked to Parkinson’s disease, a movement condition dementia with Lewy bodies, which causes cognitive decline and multiple system atrophy, in which the ability to regulate involuntary functions such as blood pressure, breathing, and bladder and bowel function deteriorates. National Institutes of Health (NIH) - will help to lay the groundwork for clinical trials focused on stopping the troublesome condition from progressing into a debilitating disease. This grant - from the National Institute on Aging (NIA) and the National Institute of Neurological Disorders and Stroke (NINDS), both of the U.S. Louis, the Mayo Clinic in Rochester, Minn., has received a five-year grant expected to total $35.1 million USD to develop biomarkers that indicate which people with the sleep disorder will go on to develop neurodegenerative diseases, which specific diseases, when symptoms will arise, and how quickly the diseases will progress. People with the disorder have a 50 to 80 per cent chance of developing a serious neurodegenerative disease within a decade of diagnosis.Īn international team led by researchers at The Neuro (Montreal Neurological Institute-Hospital) of McGill University, Washington University School of Medicine in St. Such actions are more than just a nuisance. While sleeping safely in bed, for example, they might throw up their arms to catch an imaginary ball, or try to run from an illusory assailant. People with rapid eye movement (REM) sleep behavior disorder act out their dreams. International team seeks hidden signs of brain damage in REM behavior disorder
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |